John P. Schmid, Director at BlossomHill Therapeutics, Inc. (BLSM), bought 6,000 shares at $16.00 ($96K) on 2026-08-10, disclosed to the SEC on 2026-08-10.
Director John P. Schmid purchased $96,000 of stock at $16.00, marking the largest purchase of his career and a significant signal of confidence in the company's future. This rare reversal comes alongside a cluster of three other insider buys in the past 30 days, suggesting growing institutional conviction.
The stock is currently trading at $16.02, essentially flat with the purchase price, and sits just 2.76% below its 52-week high of $16.475.
3 other insiders bought in the last 30 days; track that momentum.
Insufficient data — needs manual review
Something here stands out, but not much.
| Filing → |
| XERS | BUY | 2024-08-12 | $10K | — | Filing → |
| XERS | BUY | 2024-05-10 | $10K | — | Filing → |
| DSGN | BUY | 2024-03-25 | $166K | — | Filing → |